Jane Street
CRVS icon

Jane Street’s Corvus Pharmaceuticals CRVS Stock Holding History

Jane Street’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Sell
20,200
-21,700
-52% -$301K ﹤0.01% 9204
2026
Q1 		$613K Buy
41,900
+26,200
+167% +$418K ﹤0.01% 7563
2025
Q4 		$121K Buy
+15,700
New +$124K ﹤0.01% 10074
2025
Q2 		– Sell
-12,200
Closed -$38.8K – 9789
2025
Q1 		$38.8K Sell
12,200
-57,000
-82% -$268K ﹤0.01% 9054
2024
Q4 		$370K Buy
+69,200
New +$517K ﹤0.01% 7375
2022
Q1 		– Sell
-10,300
Closed -$25K – 10377
2021
Q4 		$25K Sell
10,300
-75,000
-88% -$291K ﹤0.01% 9738
2021
Q3 		$413K Buy
+85,300
New +$252K ﹤0.01% 7626

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jane Street's CRVS Position: Q2 2026 in Review

Jane Street sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 44,473 shares — an estimated $617K sold.

Jane Street first reported a position in CRVS in Q3 2021 and held it in 11 quarters. The position peaked at $2.91M in Q4 2025. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Jane Street reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 44,473 Corvus Pharmaceuticals shares in Q2 2026, an estimated $617K.
  • Jane Street first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 11 quarters.
  • Jane Street's Corvus Pharmaceuticals position peaked at $2.91M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.